Cross Country Healthcare, Inc. (CCRN)
Valuation Overview•Is Cross Country Healthcare, Inc. Overvalued or Undervalued?
Commands a premium valuation multiple over its peers, likely pricing in superior execution.
Fragile underlying quality score of 33/100; weak margins or elevated debt leverage warrant caution.
Analysts remain cautious, with consensus price targets indicating limited room for upside expansion.
Verdict: Mixed fundamental profile with offsetting strengths and weaknesses.
Wall Street is cautious, forecasting potential downside alongside robust expected earnings growth. However, capital return yields remain modest, driven predominantly by aggressive share repurchases.
Returns capital exclusively via buybacks — no active dividend
CCRN struggles with subpar profitability and pressured margins. This is backed by a fortress balance sheet, holding significant net cash ($106M) and minimal debt risk.
The company is facing top-line contraction (-27.8% 3Y CAGR) paired with stable bottom-line earnings. However, profitability remains a major concern with severely compressed operating margins (-2.1%).
| Financial Metric | Trend (12Q) | Latest Qtr | 1Y Growth | 3Y CAGR | 5Y CAGR | 10Y CAGR |
|---|---|---|---|---|---|---|
| Revenue | $241.1M | -21.6% | -27.8% | +4.7% | +3.2% | |
| EBITDA | $1.7M | — | -63.9% | — | — | |
| Net Income | -$4.3M | -551.6% | — | — | — | |
| EPS (Diluted) | $-0.14 | -565.9% | — | — | — | |
| Free Cash Flow | $3.3M | -64.0% | -31.6% | +12.2% | — |
| Metric | TTM | 3Y Avg | 5Y Avg | 10Y Avg |
|---|---|---|---|---|
| Gross Margin | 19.8% | 20.5% | 21.2% | 23.4% |
| Operating Margin | -2.1% | 1.3% | 4.4% | 1.9% |
| Net Margin | -9.8% | -2.2% | 1.6% | 0.3% |
| FCF Margin | 4.0% | 7.9% | 4.5% | 3.5% |
| Quarter | EPS Est. | EPS Act. | Surprise | EPS | Rev |
|---|---|---|---|---|---|
| Q2'26Latest | $-0.05 | $-0.03 | +40.0% | ||
| Q1'26 | $0.03 | $-0.06 | -300.0% | ||
| Q4'25 | $0.04 | $0.03 | -25.0% | ||
| Q3'25 | $0.07 | $-0.01 | -114.3% | ||
| Q2'25 | $0.04 | $0.06 | +50.0% | ||
| Q1'25 | $0.11 | $0.04 | -63.6% | ||
| Q4'24 | $0.10 | $0.12 | +20.0% | ||
| Q3'24 | $0.14 | $0.10 | -28.6% |
Total return is -7.6% (1Y), lagging the benchmark by -32.6%
| Period | Total Return | vs S&P 500 (Alpha) | Dividend Contribution |
|---|---|---|---|
| YTD | +63.4% | +54.1% | — |
| 1Y | -7.6% | -32.6% | — |
| 3YCAGR | -21.2% | -40.7% | — |
| 5YCAGR | -5.9% | -19.0% | — |
| 10YCAGR | -0.5% | -13.9% | — |
The S&P 500 is at 31.3x trailing P/E — Expensive relative to historical averages.
Quick answers to common questions about Cross Country Healthcare, Inc. (CCRN) valuation, health, and returns.
Based on peer relative multiples, Cross Country Healthcare, Inc. appears Expensive versus peers compared to industry peers.
Cross Country Healthcare, Inc. has multiple valuation anchors: Peer Relative Fair Value: $3.65 | Wall Street Analyst Target: $12.50 (implying -5.1% upside). A convergence of these signals offers higher conviction.
Cross Country Healthcare, Inc. displays weak financial health with a composite quality score of 33/100, supported by a Altman Z-Score of 5.1 (safe zone), Piotroski F-Score of 6/9, Return on Invested Capital (ROIC) of -0.9%.
Cross Country Healthcare, Inc. returns capital via buybacks instead of dividends, carrying a 1.6% buyback yield and reducing outstanding shares by -2.9% in the last 12 months.
Cross Country Healthcare, Inc.'s current growth trajectory is Accelerating. The company achieved -21.6% 1Y revenue growth and -565.9% 1Y EPS growth, compared to its 3Y revenue CAGR of -27.8%.
Wall Street consensus is Hold based on 14 analysts, beating EPS expectations in 50% of recent quarters with a 1-quarter streak. The consensus price target represents a -5.1% change from current levels.
Investment risks for Cross Country Healthcare, Inc. include: -47.1% 1-year max drawdown. Volatility risk is characterized by a beta of 0.68x.
No. These computations are purely quantitative model outputs for informational purposes. They do not account for qualitative management shifts or macro events. Always consult a licensed RIA before buying or selling shares.
Disclaimer: This page is for informational purposes only and does not constitute financial advice. All valuation models, scores, and target estimates are automated computations under stated assumptions and should not be relied upon as the sole basis for any investment decision.